Eye care solution capable of relieving eyeball aging

Abstract

The invention relates to an eye care solution capable of relieving eyeball aging, and belongs to the technical field of care solutions. The eye care solution capable of relieving eyeball aging is prepared from the following raw materials in percentage by mass: 1.5 to 2.5 percent of glycerol, 0.78 to 0.82 percent of sodium chloride, 0.01 to 0.02 percent of water-soluble lutein, 0.1 to 0.15 percent of taurine, 0.03 to 0.05 percent of hydrolyzed pearl, 0.2 to 0.28 percent of boric acid, 0.05 to 0.07 percent of borax, 0.02 to 0.04 percent of edetate disodium, 0.0035 to 0.0045 percent of benzalkonium chloride, 0.002 to 0.005 percent of borneol, 0.005 to 0.01 percent of menthol and the balance of purified water. The eye care solution disclosed by the invention aims at office workers who use eyes for a long time, middle-aged and elderly people who are susceptible to eyeball aging, asthenopia and dry eye surfaces, realizes mild moisturizing and relieving of the eye surfaces, supplements nutrients required by eye tissue metabolism, resists eyeball aging caused by light damage, and has the effects of relieving eye fatigue and relieving eye fatigue. Meanwhile, eyeball senescence related eye discomfort such as eye dryness, eye acerbity and blurred vision is relieved, bacteriostatic protection of the ocular surface microenvironment is considered, the physiological state of eye tissue can be improved after long-term use, and the eyeball senescence process is delayed.

Description

Technical Field

[0001] This invention relates to the field of eye care solution technology, and more specifically to an eye care solution that can alleviate eye aging. Background Technology

[0002] As we age, the various structures of the human eye undergo physiological degeneration. The lens loses elasticity and transparency, increasing the risk of presbyopia and cataracts. Degeneration of retinal pigment epithelial cells and photoreceptor cells leads to macular degeneration and decreased retinal function, resulting in blurred vision and visual field defects. Simultaneously, a decrease in the number of conjunctival mucous cells, insufficient tear secretion, and reduced tear film stability can cause dry eye syndrome, accompanied by discomfort such as dryness, irritation, and a foreign body sensation. Modern environmental factors such as excessive screen time, excessive blue light exposure, and air pollution further accelerate the aging process of the eye, causing this problem to affect younger people. It not only troubles middle-aged and elderly people but is also increasingly impacting young people who use electronic devices for extended periods, becoming a pressing national eye health issue that needs to be addressed.

[0003] While managing eye strain and slowing down eye aging can be achieved through measures like controlling screen time, avoiding excessive blue light and UV exposure, and regularly performing eye massages and exercises, these methods cannot fundamentally replenish the nutrients needed by the eyes or repair damaged eye tissues. Dietary adjustments, such as consuming foods rich in vitamin C, lutein, and omega-3 fatty acids, provide basic nutritional support and protect against free radical damage to eye cells. However, nutrient absorption is inefficient and cannot target specific areas of eye aging, resulting in limited relief. In contrast, eye care solutions, as convenient, gentle, and long-term usable preparations, act directly on the eye surface, quickly replenishing tears and moisturizing the ocular surface. Furthermore, by adding functional ingredients, they can specifically nourish eye tissues, eliminate free radicals, and repair damaged corneal and retinal cells, playing an irreplaceable core role in alleviating discomfort related to eye aging and slowing down the aging process.

[0004] Current eye care solutions have limitations in their ingredient design. Most products focus solely on moisturizing and hydrating, only relieving surface discomfort such as dryness and irritation, without adding targeted anti-aging active ingredients. Therefore, developing an eye care solution with a reasonable formula, clear efficacy, safety, gentleness, and the ability to address the root causes of eye aging has become a pressing technical challenge in this field. Summary of the Invention

[0005] In view of this, the present invention provides an eye care solution that can alleviate eye aging. It is suitable for various groups of people, including office workers who use their eyes for long periods of time, middle-aged and elderly people who are prone to eye aging, and people with eye fatigue accompanied by dry eye. It can gently moisturize and soothe the eye surface, replenish the nutrients needed for eye tissue metabolism, resist eye aging caused by light damage, and relieve eye discomfort related to eye aging such as dry eyes, eye irritation, and blurred vision. It also takes into account the antibacterial protection of the eye surface microenvironment. Long-term use can improve the physiological state of eye tissue and delay the process of eye aging.

[0006] To achieve the above objectives, the present invention mainly adopts the following technical solutions: First, this invention provides an eye care solution that can alleviate eye aging, composed of the following raw materials in weight percentages: 1.5-2.5% glycerin, 0.78-0.82% sodium chloride, 0.01-0.02% water-soluble lutein, 0.1-0.15% taurine, 0.03-0.05% hydrolyzed pearl, 0.2-0.28% boric acid, 0.05-0.07% borax, 0.02-0.04% disodium edetate, 0.0035-0.0045% benzalkonium chloride, 0.002-0.005% borneol, 0.005-0.01% menthol, and the balance being purified water.

[0007] Its beneficial effects are as follows: Glycerin is a mild polyol moisturizer that is compatible with the tolerance characteristics of the ocular mucosa. Its molecules can form hydrogen bonds with water molecules, which can quickly replenish the moisture lost by the tear film on the ocular surface during the aging process of the eyeball. At the same time, it forms a thin moisturizing film on the ocular surface, locks in the moisture of the tear film, maintains the integrity of the tear film, relieves the problems of reduced tear secretion, dry eyes and irritation caused by aging, and can also reduce friction between ocular surface tissues, protect the corneal epithelial cells that are more fragile after aging, and reduce the damage of external stimuli to the ocular surface.

[0008] Sodium chloride, as a physiological osmotic pressure regulator, can accurately simulate the osmotic pressure of human physiological tears. As the eyeball ages, the osmotic pressure regulation ability of the ocular surface mucosal cells decreases. Sodium chloride can help maintain the osmotic pressure balance between the contact lens solution and the ocular surface environment, maintain the normal physiological morphology and metabolic function of the conjunctiva and corneal cells, and avoid osmotic pressure imbalance from aggravating eye discomfort caused by eyeball aging.

[0009] Hydrolyzed pearl is a small-molecule pearl extract. After hydrolysis, it releases a variety of amino acids, minerals, and trace elements. During the aging process of the eyeball, the ocular surface tissue will experience nutrient loss and a decline in cell metabolism. The nutrients in hydrolyzed pearl can be absorbed by the corneal and conjunctival cells of the ocular surface, replenishing the nutrients needed for cell metabolism, enhancing the proliferation and repair capabilities of ocular surface cells, delaying the aging process of ocular surface tissues, and forming a thin, nutrient-protective film on the ocular surface to reduce direct stimulation of the ocular surface by the external environment.

[0010] Water-soluble lutein is a core nutrient for combating retinal aging. Its water-soluble properties allow it to remain stable in contact lens solutions and be readily absorbed by the ocular surface. Lutein is a characteristic nutrient of the macular region of the human retina. As we age, the lutein content in the macular region gradually decreases, leading to a decline in the macula's ability to block blue light and its antioxidant capacity. Water-soluble lutein can replenish the lutein content in the macular region, effectively blocking blue light from electronic devices and natural light from damaging retinal cells, clearing free radicals in the retina, protecting the normal physiological function of the macular region, and delaying retinal aging and degeneration.

[0011] Taurine is a free amino acid abundant in eye tissues and an important functional substance for eye metabolism. It participates in the energy metabolism and antioxidant process of corneal epithelial cells, enhances the repair ability of corneal epithelial cells, and improves the problems of corneal epithelial fragility, easy damage, and slow repair caused by aging. At the same time, it can also regulate the ion balance of retinal nerve cells, maintain the normal function of retinal nerve conduction, reduce the problem of age-related decline in retinal nerve cell activity, and protect the physiological function of the visual system.

[0012] Borneol is a soothing ingredient for the eyes. It has good lipophilicity and can quickly penetrate into the superficial tissues of the eye surface to rapidly exert a cooling and soothing effect, relieving discomfort symptoms such as eye swelling, eye dryness, and eye soreness caused by eye aging and eye fatigue. At the same time, borneol also has a mild antibacterial effect, which can help inhibit the growth of a small number of harmful microorganisms on the eye surface, reduce mild inflammation of the eye surface caused by microorganisms, prevent further damage to aging eye tissues by inflammation, and maintain the stability of the eye surface microenvironment.

[0013] Menthol and borneol work synergistically to provide a cooling and soothing effect, stimulating the cooling receptors on the surface of the eye to quickly relieve dryness, soreness, and fatigue caused by eye aging, thus improving comfort after eye use. Its gentle volatility keeps the surface of the eye fresh and reduces the adhesion of eye secretions. At the same time, the mild antibacterial properties of menthol, together with borneol, boric acid, and other ingredients, create a synergistic antibacterial effect, further reducing the risk of microbial growth on the surface of the eye, which is suitable for the decreased resistance of the eyes after aging.

[0014] Boric acid, a weak acid, is a core component of the pH adjustment system in contact lens solutions, while also possessing mild antibacterial properties. As the eye ages, the tolerance of the ocular surface mucosa to acidic and alkaline environments significantly decreases. The combination of boric acid and borax creates a stable buffer system, precisely stabilizing the pH of the solution within a range close to the slightly acidic pH of human tears, maintaining the acid-base balance of the ocular surface mucosa, and preventing damage to ocular surface cells from pH fluctuations. Borax enhances the antibacterial effect of boric acid; the two work synergistically to expand the antibacterial range and improve the antibacterial effect, effectively reducing the growth of harmful microorganisms on the ocular surface and lowering the risk of eye infections. Simultaneously, borax also improves the stability of various water-soluble active ingredients in the solution, preventing their decomposition and inactivation due to environmental changes.

[0015] Disodium edetate is a highly effective chelating agent that can effectively chelate trace metal ions in contact lenses and on the ocular surface without causing irritation. During the aging process of the eye, the antioxidant capacity of ocular tissues declines, while trace metal ions catalyze the generation of free radicals in the body, accelerating the oxidative aging of ocular surface and retinal cells. Disodium edetate can lock in metal ions through chelation, reducing the generation of free radicals and mitigating the impact of oxidative damage on ocular tissues. Simultaneously, it can prevent metal ions from forming complexes with active ingredients such as lutein and taurine in the contact lens solution, avoiding the inactivation of these active ingredients, improving the overall stability of the solution, and ensuring the effective functioning of each component.

[0016] Benzalkonium chloride is a quaternary ammonium salt cationic surfactant and the core antibacterial ingredient in contact lens solutions, achieving a balance between highly effective antibacterial action and gentleness on mucous membranes. Its mechanism of action involves disrupting the cell membrane structure of microorganisms and inhibiting their metabolic processes. It effectively kills or inhibits common pathogens on the ocular surface, such as Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa, reducing the risk of eye infections and catering to the physiological characteristics of decreased resistance in eye tissues due to aging.

[0017] Water, as the base solvent of the eye care solution of this invention, constitutes the remainder of the raw material ratio and serves as the carrier for all water-soluble active ingredients. Its purity is suitable for use on the ocular mucosa. Water can fully dissolve all water-soluble raw materials such as glycerin, sodium chloride, and lutein, ensuring that each active ingredient is evenly dispersed in the solution and that each ingredient can act evenly on the ocular surface during use. At the same time, it can directly replenish the moisture lost through insufficient tear secretion during the aging process of the eyeball, quickly relieve dry eye symptoms, maintain the moist state of the ocular surface, and provide a stable medium environment for the normal metabolism of ocular surface cells and the penetration and absorption of each active ingredient. This is the foundation for the moisturizing, nourishing, and soothing effects of the solution.

[0018] Preferably, the eye care solution is composed of the following raw materials in the indicated weight percentages: 2.0% glycerin, 0.81% sodium chloride, 0.015% water-soluble lutein, 0.11% taurine, 0.04% hydrolyzed pearl, 0.26% boric acid, 0.065% borax, 0.035% disodium edetate, 0.0042% benzalkonium chloride, 0.0045% borneol, 0.009% menthol, and the balance being purified water.

[0019] Secondly, the present invention also provides a method for preparing the above-mentioned eye care solution, comprising the following steps: S1 Raw Material Preparation Weigh the raw materials according to the specified proportions and set aside.

[0020] S2 configuration basic buffer Add purified water to a sterile preparation vessel, then add boric acid, borax, and sodium chloride in sequence. Start stirring until completely dissolved to obtain a stable buffer salt solution.

[0021] S3 contains active and antibacterial ingredients. Disodium edetate, taurine, hydrolyzed pearl, water-soluble lutein, glycerin, benzalkonium chloride, borneol, and menthol were added sequentially to a buffer salt solution. The mixture was stirred and then sonicated to obtain the eye care solution.

[0022] S4 sterilization The eye care solution is filtered through a sterile microporous membrane, the filtrate is filled, and then sealed using a sterile sealing process.

[0023] Preferably, the purified water in step S2 is at 25~30℃; the stirring speed is 150~200 r / min, and the stirring time is 15~20 min.

[0024] Preferably, the stirring speed in step S3 is 200~250 r / min and the time is 20~30 min; the ultrasonic treatment power is 100~200 W and the time is 10~15 min.

[0025] Preferably, the pore size of the sterile microporous filter membrane in step S4 is 0.22 μm.

[0026] In summary, compared with the prior art, this application provides an eye care solution that can alleviate eye aging, and its beneficial effects are as follows: This invention constructs a targeted anti-aging system for the eye through the synergistic effect of multiple components. Water-soluble lutein can quench free radicals, resist photo-oxidative damage, and protect photoreceptor cells and macular tissue on the ocular surface from age-related oxidative damage. Taurine replenishes retinal nutrition, promotes mucosal cell metabolism and repair, and delays cell function decline. The two work synergistically to achieve the core anti-aging effect of "antioxidant cell protection + nutrition to promote repair". At the same time, the moisturizing and repairing film formed by glycerin and hydrolyzed pearl can maintain the integrity of the ocular mucosal barrier and reduce ocular surface aging accelerated by barrier damage. Boric acid, borax, and low-concentration benzalkonium chloride stabilize the physiological environment of the ocular surface and inhibit pathogenic bacteria, avoiding premature ocular aging caused by inflammatory damage. The scientific ratio of each component and their complementary effects delay the aging process of the eye from multiple dimensions such as antioxidation, nutrition, barrier protection, and damage prevention, taking into account both anti-aging efficacy and ocular surface physiological compatibility. Detailed Implementation

[0027] The technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Example 1

[0028] S1 Raw Material Preparation Weigh the raw materials according to the following percentages by mass: glycerin 2.3%, sodium chloride 0.80%, water-soluble lutein 0.018%, taurine 0.12%, hydrolyzed pearl 0.035%, boric acid 0.25%, borax 0.06%, disodium edetate 0.03%, benzalkonium chloride 0.0040%, borneol 0.003%, menthol 0.006%, with the remainder being purified water.

[0029] S2 configuration basic buffer Add purified water to a sterile preparation tank, keep the purified water temperature at 25℃, add boric acid, borax and sodium chloride in sequence, stir at 150r / min for 20min until completely dissolved, and obtain a stable buffer salt solution. S3 contains active and antibacterial ingredients. Add disodium edetate, taurine, hydrolyzed pearl, water-soluble lutein, glycerin, benzalkonium chloride, borneol, and menthol to a buffer salt solution in sequence. Stir at 200 r / min for 30 min, and then sonicate at 100 W for 15 min to obtain the eye care solution. S4 sterilization The eye care solution is filtered through a 0.22μm sterile microporous membrane, the filtrate is filled, and then sealed using a sterile sealing process. Example 2

[0030] S1 Raw Material Preparation Weigh the raw materials according to the following percentages by mass: glycerin 1.8%, sodium chloride 0.79%, water-soluble lutein 0.012%, taurine 0.14%, hydrolyzed pearl 0.048%, boric acid 0.23%, borax 0.055%, disodium edetate 0.025%, benzalkonium chloride 0.0038%, borneol 0.004%, menthol 0.008%, with the remainder being purified water, for later use.

[0031] S2 configuration basic buffer Add purified water to a sterile preparation tank, keep the purified water temperature at 25℃, add boric acid, borax and sodium chloride in sequence, stir at 200r / min for 20min until completely dissolved, and obtain a stable buffer salt solution. S3 contains active and antibacterial ingredients. Add disodium edetate, taurine, hydrolyzed pearl, water-soluble lutein, glycerin, benzalkonium chloride, borneol, and menthol to the buffer salt solution in sequence. Stir at 250 r / min for 30 min, and then sonicate at 150 W for 15 min to obtain the eye care solution. S4 sterilization The eye care solution is filtered through a 0.22μm sterile microporous membrane, the filtrate is filled, and then sealed using a sterile sealing process. Example 3

[0032] S1 Raw Material Preparation Weigh the raw materials according to the following percentages by mass: glycerin 2.0%, sodium chloride 0.81%, water-soluble lutein 0.015%, taurine 0.11%, hydrolyzed pearl 0.04%, boric acid 0.26%, borax 0.065%, disodium edetate 0.035%, benzalkonium chloride 0.0042%, borneol 0.0045%, menthol 0.009%, with the remainder being purified water.

[0033] S2 configuration basic buffer Add purified water to a sterile preparation tank, keep the purified water temperature at 30℃, add boric acid, borax and sodium chloride in sequence, stir at 150 r / min for 15 min until completely dissolved, and obtain a stable buffer salt solution. S3 contains active and antibacterial ingredients. Add disodium edetate, taurine, hydrolyzed pearl, water-soluble lutein, glycerin, benzalkonium chloride, borneol, and menthol to a buffer salt solution in sequence. Stir at 200 r / min for 20 min, and then sonicate at 200 W for 10 min to obtain the eye care solution. S4 sterilization The eye care solution is filtered through a 0.22μm sterile microporous membrane, the filtrate is filled, and then sealed using a sterile sealing process.

[0034] Human retinal pigment epithelial cells (RPE-1) in the logarithmic growth phase were harvested and the cell concentration was adjusted to 1×10⁻⁶. 5 Cells were seeded at a density of 100 μL / mL in 96-well plates and incubated at 37°C with 5% CO2 for 24 h. After the cells reached 80% confluence, the original culture medium was discarded, and the cells were divided into groups as follows. The total culture time was 48 h: Blank control group: DMEM medium containing 10% fetal bovine serum was added, without oxidative damage treatment or the addition of care solution; Oxidative model group: Serum-free DMEM medium with 200 μmol / L H2O2 was added to induce oxidative stress damage in cells, without adding care solution; Experimental group: Serum-free DMEM culture medium containing 200 μmol / L H2O2+ at a volume concentration of 10% as prepared in Example 3 was added to induce oxidative damage while the eye care solution was administered for intervention.

[0035] After 48 hours of culture, intracellular ROS levels, SOD activity in cell supernatant, and MDA content in cell supernatant were measured sequentially. These three indicators reflect the degree of cellular oxidative stress from different perspectives. The detection procedure was performed according to the kit instructions. The results are shown in the table below: The results showed that the ROS fluorescence intensity and MDA content in the oxidation model group were significantly higher than those in the blank control group, while SOD activity was significantly lower, confirming the successful establishment of the oxidation model and the obvious accumulation of reactive oxygen species, damage to the endogenous antioxidant system, and lipid peroxidation damage in the cells. In contrast, the experimental group using the eye care solution of this invention showed significantly lower ROS fluorescence intensity and MDA content compared to the oxidation model group, while SOD activity significantly increased, and all three indicators were close to the levels of the blank control group. This indicates that the eye care solution of this invention can effectively remove excess reactive oxygen species in retinal pigment epithelial cells, protect the activity of the endogenous antioxidant enzyme SOD, rebuild the cell's own antioxidant defense system, and significantly inhibit lipid peroxidation induced by oxidative stimulation, reducing cellular oxidative damage and reversing the abnormal state of cellular oxidative stress. Furthermore, there were no significant differences in various oxidative stress indicators between the experimental group and the blank control group, indicating that the eye care solution of this invention, while exerting an antioxidant protective effect, does not cause oxidative disturbance to retinal pigment epithelial cells under normal conditions, and does not disrupt the normal oxidation-antioxidant balance of cells, demonstrating both good antioxidant activity and safety at the in vitro cellular level. Therefore, the eye care solution of the present invention has a significant protective effect on human retinal pigment epithelial cells under oxidative stress, providing reliable in vitro cell experimental evidence for its use in preventing or alleviating eye problems related to oxidative damage of retinal pigment epithelial cells.

[0036] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. An eye care solution that can alleviate aging of eyeballs, characterized by, The eye care solution is prepared from the following raw materials in the following mass percentages: glycerin 2.0%, sodium chloride 0.81%, water-soluble lutein 0.015%, taurine 0.11%, hydrolyzed pearl 0.04%, boric acid 0.26%, borax 0.065%, disodium edetate 0.035%, benzalkonium chloride 0.0042%, menthol 0.0045%, menthol 0.009%, and the balance being purified water.

2. The eye treatment fluid of claim 1, wherein The eye care solution is prepared from the following raw materials in the following mass percentages: glycerin 2.0%, sodium chloride 0.81%, water-soluble lutein 0.015%, taurine 0.11%, hydrolyzed pearl 0.04%, boric acid 0.26%, borax 0.065%, disodium edetate 0.035%, benzalkonium chloride 0.0042%, menthol 0.0045%, menthol 0.009%, and the balance being purified water.

3. A method of preparing an eye care solution as claimed in any one of claims 1 to 2, characterised in that, The method comprises the following steps: S1 raw material preparation The raw materials are weighed according to the proportions and prepared for use; S2 preparation of a basic buffer solution Purified water is taken and added to a sterile preparation tank, and boric acid, borax and sodium chloride are sequentially added. Stirring is started until complete dissolution, and a stable buffer salt solution is obtained; S3 addition of active and bacteriostatic ingredients Disodium edetate, taurine, hydrolyzed pearl, water-soluble lutein, glycerin, benzalkonium chloride, menthol and menthol are sequentially added to the buffer salt solution, and stirring and mixing are performed. Ultrasonic treatment is performed to obtain the eye care solution; S4 sterilization The eye care solution is filtered through a sterile microporous filter membrane, the filtrate is filled, and a sterile sealing process is used for packaging.

4. The method of claim 3, wherein, In step S2, the purified water is at 25-30°C; the stirring speed is 150-200 r / min, and the stirring time is 15-20 min.

5. The method of claim 3, wherein, In step S3, the stirring speed is 200-250 r / min, and the stirring time is 20-30 min; the ultrasonic treatment power is 100-200 W, and the time is 10-15 min.

6. The method of claim 3, wherein, In step S4, the pore size of the sterile microporous filter membrane is 0.22 μm.